NCT05192460 - Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions

Gastric CancerEsophageal CancerLiver Cancer

Interventions

BIOLOGICAL

neoantigen tumor vaccine with or without PD-1/L1

In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1/L1.

Trial Locations (1)

100039

RECRUITING

PLA General Hospital, Beijing